EGFR and cancer: Two recent studies reported that the EGFR pathway is involved in the regulation of PD‐L1 expression in EGFR‐mutant human non‐small‐cell lung cancer (NSCLC) cells, whereby inhibition of EGFR signalling decreased PD‐L1 expression in some EGFR‐mutant NSCLC cells, suggesting that tumour PD‐L1 expression may be regulated by cancer‐driven mutation.27, 28 Five of the human MPM cell lines (H290, H2052, 211H, H28 and MS‐1) used in our study had a low p‐YAP (S127)/YAP ratio and high GTIIC reporter activity.